Uncategorized

Will Glaxo do anything to keep Avandia on the market?

Federal regulators have debated for several years whether or not diabetes drug Avandia should remain on the market. The problem is that it seems to raise the risk of heart attacks and Avandia is not the only drug of its kind available.

But Glaxo, which makes Avandia, was frightened that one of its big sellers would get yanked from the shelves, so the company began pressuring scientists, including Dr. John Buse at UNC, to drop the criticism. The drug maker’s behavior was appalling.

Now the FDA is examining the drug again and asked the company to send a letter to physicians summarizing the federal hearing where researchers presented evidence against Avandia. The doctors are part of a drug trial comparing Avandia to another drug. But the trial raises ethical issues because Avandia may be dangerous.

Let’s just say that more than a few people thought the letter sent by Glaxo glossed over some critical information.

This is a crucial issue for many consumers around the country, and many lives are certainly at stake. Glaxo should stop pushing Avandia at all costs, and it’s time we let the science speak.

4 Comments


  1. […] News: Diabetes Meds Associated With Fracture RiskNurse.comTheHeart.Org -The Progressive Pulse (blog) -FiercePharmaall 29 news […]

  2. […] Official, Advisors Call GSK Letter About Avandia Review MisleadingAboutLawsuits.comNurse.com -The Progressive Pulse (blog) -FiercePharmaall 33 news […]

  3. […] drug "as safe as rival"Pharmacy EuropeNurse.com -AboutLawsuits.com -The Progressive Pulse (blog)all 55 news […]

  4. PrettyOldLady

    August 25, 2010 at 1:24 pm

    This makes me boiling ANGRY!! The diabetes drug makers make bilions every month of the people this is SICK. The FDA always approves the drugs and then recalls them after the drug companies get richer. A European filmmaker has been reversing diabetes in 10 countries WITHOUT MEDICATIONS! and the drug companies do not promote the story

    just google SPIRIT HAPPY DIET

Check Also

Context is key for understanding Insurance Commissioner’s Affordable Care Act comments

Many people were surprised to see a story ...

Top Stories from NCPW

  • News
  • Commentary

Weeks after the top school board member in Robeson County predicted the southeastern North Carolina [...]

A pivotal legislative task force may be just beginning its dive into North Carolina’s school funding [...]

The controversy over “Silent Sam,” the Confederate monument on UNC’s Chapel Hill campus, has been ra [...]

North Carolina tries to mine its swine and deal with a poop problem that keeps piling up A blanket o [...]

With Republicans on Capitol Hill and in the White House desperate to post a big legislative win, the [...]

Latest court system mess is directly linked to the Right’s ideological war on public structures Some [...]

Republicans in Congress are rushing to advance a tax reform bill that balloons the federal deficit s [...]

The post Charitable donations and the GOP’s chopping block appeared first on NC Policy Watch. [...]

Spotlight on Journalism

We invite you to join a special celebration of investigative journalism! The evening will feature Mike Rezendes, a member of the Pulitzer Prize-winning Boston Globe Spotlight Team known for their coverage of the cover-up of sexual abuse in the Catholic Church.

Tickets available NOW!

Spotlight On Journalism

This event will benefit NC Policy Watch, a project of the North Carolina Justice Center. Sponsorship opportunities available now!

Featured | Special Projects

NC Budget 2017
The maze of the NC Budget is complex. Follow the stories to follow the money.
Read more


NC Redistricting 2017
New map, new districts, new lawmakers. Here’s what you need to know about gerrymandering in NC.
Read more